Atlanta, GA – Scibility Media – 11/19/2014.
This article discusses two companies: NeoStem Inc(NASDAQ:NBS) and Inter Parfums, Inc.(NASDAQ:IPAR)
NeoStem Inc(NASDAQ:NBS) traded for as little as $4.50 yesterday, a new 52 week low for the company. The company announced initial positive data for its Phase 2 PreSERVE AMI clinical trial on Nov. 17th, 2014, which included a statistically significant mortality benefit and dose-dependent reduction in SAEs.
The company presented at the Stifel 2014 Healthcare Conference in New York City on Nov. 18th. On Thursday, NeoStem will be presenting at the Jefferies 2014 Global Healthcare Conference.
The company, which has a market capitalization of $241.20 million, had a trading volume of 4.14 million yesterday. This figure is 3.85 million lower than NeoStem’s three month average volume of 0.29 million, indicating that investor interest in the stock has increased. The company’s CFO will then present at German Equity Forum 2014.
Inter Parfums, Inc.(NASDAQ:IPAR) also traded for a new 52 week low of $24.81 during yesterday’s trading. The loss came one day after the company provided preliminary 2015 guidance, which included a call for a net sales growth of approximately 7%. Inter Parfums expects a net sales of approximately $500 million for 2015.
The company reported its third quarter financial results on Nov. 10th. The figures included a net sales year-over-year increase of 6% from $126.8 million to $134.2 million.
Like NeoStem, this company has also seen investor interest in its stock increase. While Inter Parfums has a three month average volume of 0.12 million, the company had a volume of 0.66 million yesterday.
EquiPress.com is a non-advertisement based network (currently in limited release) designed for investors to discover and communicate with publicly traded companies in real-time.
Sign-up for free now to experience the full benefits of EquiPress pre-launch.
Discover and communicate with companies you would otherwise never have seen based on your interests, company news, personalized news feeds, and one-on-one communications with no middle-men nor advertisements. Read our no advertisements pledge.
Can’t find your company on EquiPress? Send us an email to firstname.lastname@example.org and we will contact them for you.
Interested in a one month free trial? Get access to our private investor network, real-time news distribution, automatic disclaimers, corporate analytics, verified public profile, and industry-wide marketing of your corporate news.
Disclosure: EquiPress is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. EquiPress does not hold any equity or financial interest in any publicly traded company. EquiPress provides a uniform subscription based service to all publicly traded companies on a monthly basis at a rate of $495 to provide investor awareness. EquiPress receives only cash compensation from clients. Despite the relationship, EquiPress maintains a neutral stance (nonbiased) on any investment related opinions and exists solely for the purpose of allowing investors to communicate with the publicly traded companies in an effort to establish for themselves investment considerations. Investors should always conduct their own due diligence with any potential investment. Always seek help from a professional financial advisor. Please visit www.equipress.com for complete risks and disclosures.